Effects of Aripiprazole and Haloperidol on Fos-like Immunoreactivity in the Prefrontal Cortex and Amygdala
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: Aripiprazole, a dopamine system stabilizer, shows efficacy against both negative symptoms and positive symptoms in patients with schizophrenia. The aim of this study was to investigate the effects of aripiprazole and haloperidol on c-FOS expression in rat brain. Methods: Aripiprazole (1, 10 and 30 mg/kg, i.p.) and haloperidol (0.1 and 1 mg/kg, i.p.) were administered to adult Male Sprague-Dawley rats. After 2 h of drug or vehicle administration, the rats were killed and their brains were removed and perfused with fixative, then cut into 40 μm slices on a freezing microtome. Brain regions of interest were the medial prefrontal cortex (mPFC), the nucleus accumbens core and shell (NAC-C and NAC-S), the hippocampus (CA1, CA3 and DG), the central amygdala (Ce), the basolateral amygdala (BL) and the temporal cortex (Tc). Immunohistochemistry was performed to label cell bodies containing c-FOS. Results: The administration of aripiprazole at all doses (1, 10 or 30 mg/kg) resulted in greater Fos-like immunoreactivity (FLI)in the investigated brain areas, as compared to the vehicle. Comparable increases in FLI were demonstrated in the NAC-C and NAC-S in response to both aripiprazole and haloperidol treatment. The administration of haloperidol (0.1 or 1 mg/kg) also resulted in greater FLI in the investigated brain areas, except the mPFC, where no changes were observed. In the Ce and BL, a significant increase in Fos-positive neurons was observed only with 0.1 mg/kg of haloperidol. Conclusion: Both aripiprazole and haloperidol increased FLI in limbic areas, which are considered important targets of antipsychotic drugs. The differential action of aripiprazole on FLI in the amygdala and mPFC as compared to haloperidol may be a good way to differentiate atypical from typical antipsychotics.
Abstract
Objective: Aripiprazole, a dopamine system stabilizer, shows efficacy against both negative symptoms and positive symptoms in patients with schizophrenia. The aim of this study was to investigate the effects of aripiprazole and haloperidol on c-FOS expression in rat brain. Methods: Aripiprazole (1, 10 and 30 mg/kg, i.p.) and haloperidol (0.1 and 1 mg/kg, i.p.) were administered to adult Male Sprague-Dawley rats. After 2 h of drug or vehicle administration, the rats were killed and their brains were removed and perfused with fixative, then cut into 40 μm slices on a freezing microtome. Brain regions of interest were the medial prefrontal cortex (mPFC), the nucleus accumbens core and shell (NAC-C and NAC-S), the hippocampus (CA1, CA3 and DG), the central amygdala (Ce), the basolateral amygdala (BL) and the temporal cortex (Tc). Immunohistochemistry was performed to label cell bodies containing c-FOS. Results: The administration of aripiprazole at all doses (1, 10 or 30 mg/kg) resulted in greater Fos-like immunoreactivity (FLI)in the investigated brain areas, as compared to the vehicle. Comparable increases in FLI were demonstrated in the NAC-C and NAC-S in response to both aripiprazole and haloperidol treatment. The administration of haloperidol (0.1 or 1 mg/kg) also resulted in greater FLI in the investigated brain areas, except the mPFC, where no changes were observed. In the Ce and BL, a significant increase in Fos-positive neurons was observed only with 0.1 mg/kg of haloperidol. Conclusion: Both aripiprazole and haloperidol increased FLI in limbic areas, which are considered important targets of antipsychotic drugs. The differential action of aripiprazole on FLI in the amygdala and mPFC as compared to haloperidol may be a good way to differentiate atypical from typical antipsychotics.
참고문헌 (25)
- Robertson GS, "Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity", Pharmacol Exp Ther, 271, pp.1058~1066 (1994)
- Lidow MS, "The cerebral cortex: a case for a common site of action of antipsychotics", Trends Pharmacol Sci, 19, pp.136~140 (1998)
- Pilowsky LS, "Limbic selectivity of clozapine", Lancet, 350, pp.490~491 (1997)
- Benes FM, "Evidence for altered trisynaptic circuitry in schizophrenic hippocampus", Biol Psychiatry, 46, pp.589~599 (1999)
- Young-Chul Chung, "Clozapine, but Not Haloperidol, Increases Hippocampal Dopamine and Acetylcholine Release", Clinical Psychopharmacology and Neuroscience, 1(1), pp.79~85 (2003), 대한정신약물학회
- Natesan S, "Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models", Neuropsychopharmacology, 31, pp.1854~1863 (2006)
- Ozdemir V, "Aripiprazole (Otsuka Pharmaceutical Co)", Curr Opin Investig Drugs, 3, pp.113~120 (2002)
- Nordquist RE, "Effects of aripiprazole", OPC- 14597 on motor activity, pharmacological models of psychosis, and brain activity in rats, 2008, pp.54, 405~416
- Semba J, "Differential effects of acute and chronic treatment with typical and atypical neuroleptics on c-fos mRNA expression in rat forebrain regions using non-radioactive in situ hybridization", Neurochem Int, 34, pp.269~277 (1999)
- Deutch AY, "Regionally specific effects of atypical antipsychotic drugs on striatal Fos expression: the nucleus accumbens shell as a locus of antipsychotic action", Mol Cell Neurosci, 3, pp.332~341 (1992)
- Semba J, "Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain", Neuropharmacology, 34, pp.785~791 (1995)
- Wan W, "Acute administration of typical and atypical antipsychotic drugs induces distinctive patterns of Fos expression in the rat forebrain", Brain Res, 688, pp.95~104 (1995)
- Li Z, "Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain", Eur J Pharmacol, 493, pp.75~83 (2004)
- Zocchi A, "Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex", Neurosci Lett, 387, pp.157~161 (2005)
- Assié MB, "Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin releas in rat brain", J Pharmacol Exp Ther, 315, pp.265~272 (2005)
- Deutch AY, "Effects of D2 dopamine receptor antagonists on Fos protein expression in the striatal complex and entorhinal cortex of the nonhuman primate", Synapse, 23, pp.182~191 (1996)
- Damask SP, "Differential effects of clozapine and haloperidol on dopamine receptor mRNA expression in rat striatum and cortex", Brain Res Mol Brain Res, 41, pp.241~249 (1996)
- Lidow MS, "Differential regulation of D2 and D4 dopamine receptor mRNAs in the primate cerebral cortex vs. neostriatum: effects of chronic treatment with typical and atypical antipsychotic drugs", J Pharmacol Exp Ther, 283, pp.939~946 (1997)
- Carter DM, "Patients' strategies for coping with auditory hallucinations", J Nerv Ment Dis, 184, pp.159~164 (1996)
- Beckstead RM, "Efferent connections of the substantia nigra and ventral tegmental area in the rat", Brain Res, 175, pp.191~217 (1979)
- De Olmos JS, "Amygdala, In The Rat Nervous System. 1st ed", pp.223~234 (1985), Academic Press
- Heimer L, "Groenewegen HJ, Haber SN, Harlan RE, et al. The accumbens: beyond the core-shell dichotomy", J Neuropsychiatry Clin Neurosci, 9, pp.354~381 (1997)
- Pinna A, "Differential induction of Fos-like-immunoreactivity in the extended amygdala after haloperidol and clozapine", Neuropsychopharmacology, 21, pp.93~100 (1999)
- Seillier A, "Bilateral lesions of the entorhinal cortex differentially modify haloperidol- and olanzapine-induced c-fos mRNA expression in the rat forebrain", Neuropharmacology, 45, pp.190~200 (2003)
- Kaczmarek L, "Immediate early genes and inducible transcription factors in mapping of the central nervous system function and dysfunction, In Handb Chem Neuroanat. Vol. 19." (2002), Amsterdam